| API | active pharmaceutical ingredient |
| ASO | antisense oligonucleotide |
| AUC | area under the curve |
| BA | bioavailability |
| C8 | caprylic acid, octanoic acid |
| C10 | capric acid, decanoic acid |
| COG | cost of goods |
| cEt | constrained ethyl |
| CPPs | cell-penetrating peptides |
| cLogD | calculated octanol-water distribution coefficient |
| cLogP | calculated octanol-water partition coefficient |
| EDTA | ethylenediaminetetraacetic acid |
| EPSA | experimental polar surface area |
| FDA | United States Food and Drug Administration |
| GalNAc | N-acetylgalactosamine |
| GRAS | generally recognized as safe |
| HBAs | number of hydrogen bond acceptors |
| HBDs | number of hydrogen bond donors |
| IJ | intrajejunal |
| IV | intravenous |
| MW | molecular weight |
| MPSA | molecular (3D) polar surface area in nonpolar environment |
| Ms | microsomes |
| NAr | number of aromatic rings |
| NMR | nuclear magnetic resonance |
| LD50 | median lethal dose |
| LPE | lipophilic permeability efficiency |
| NF-kB | nuclear factor kappa B |
| NOAEL | no-observed-adverse-effect level |
| P450 | cytochrome P450 |
| P-gp | P-glycoprotein |
| PO | per oral |
| TPSA | topological polar surface area |
| SC | subcutaneous |
| siRNA | small interfering RNA |
| SNAC | salcaprozate sodium |
| TEER | transepithelial electrical resistance |
| TNF-α | tumor necrosis factor α |
| TPDs | target protein degraders |